GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » United Health Products Inc (OTCPK:UEEC) » Definitions » 10-Year RORE %

United Health Products (United Health Products) 10-Year RORE % : -5.77% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is United Health Products 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. United Health Products's 10-Year RORE % for the quarter that ended in Mar. 2024 was -5.77%.

The industry rank for United Health Products's 10-Year RORE % or its related term are showing as below:

UEEC's 10-Year RORE % is ranked worse than
66.58% of 398 companies
in the Medical Devices & Instruments industry
Industry Median: 1.965 vs UEEC: -5.77

United Health Products 10-Year RORE % Historical Data

The historical data trend for United Health Products's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Health Products 10-Year RORE % Chart

United Health Products Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.94 26.38 36.87 -0.26 -2.89

United Health Products Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -1.03 1.56 -2.89 -5.77

Competitive Comparison of United Health Products's 10-Year RORE %

For the Medical Instruments & Supplies subindustry, United Health Products's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Health Products's 10-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, United Health Products's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where United Health Products's 10-Year RORE % falls into.



United Health Products 10-Year RORE % Calculation

United Health Products's 10-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.006--0.028 )/( -0.381-0 )
=0.022/-0.381
=-5.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 10-year before.


United Health Products  (OTCPK:UEEC) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


United Health Products 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of United Health Products's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


United Health Products (United Health Products) Business Description

Traded in Other Exchanges
N/A
Address
526 Commerce Circle, Suite No. 120, Mesquite, NV, USA, 89027
United Health Products Inc is a US-based company. It mainly manufactures and markets a patented hemostatic gauze for the healthcare and wound care sectors. The company's product HemoStyp is derived from regenerated oxidized cellulose, which is naturally designed to absorb exudate from superficial wounds and helps control bleeding. It markets its product to dental and medical markets as well as, sports, military and veterinary sectors, and others. The company's trademarks include Boo Boo Strips; The Ultimate Bandage; Hemostrips; CelluSTAT and Nik Fix.
Executives
Brian David Thom officer: CEO 10624 S EASTERN AVE., STE A209, HENDERSON NV 89052
Kristofer Heaton officer: Vice-President Finance, CFO 526 COMMERCE CIRCLE, STE 120, MESQUITE NV 89027
Nate Knight director C/O MORSE & MORSE, PLLC, 1400 OLD COUNTRY ROAD, SUITE 302, WESTBURY NY 11590
Louis Schiliro officer: Chief Operating Officer 10624 S. EASTERN AVENUE, STE. A209, HENDERSON NV 89052
Douglas K Beplate officer: CEO
Robert J. Denser director 10624 S. EASTERN AVE., STE. A209, HENDERSON NV 89052
John Vito Capotorto director 1090 KING GEORGES POST ROAD, SUITE 501, EDISON NJ 08837
Sherman Lazrus director
Rodney Paul Leibowitz director 420 EAST 54TH STREET, APARTMENT 15B, NEW YORK NY 10022
Michael R. Wiechnik director 11 PRESWICK DR., MEDFORD NJ 08055
Richard Rifenburgh director 2637 E. ATLANTIC BLVD., #133, POMPANO BEACH FL 33062
Phillip David Forman director, officer: President, Chairman and CEO 1090 KING GEORGES POST RD,501, EDISON NJ 08837
Jan E Chason director, officer: Chief Financial Officer 120 WALL STREET, SUITE 2401, NEW YORK NY 10005
Kelly Thomas Hickel director, officer: Chief Executive Officer 1630A 30TH STREET, SUITE 300, BOULDER CO 80301
Patrick Donelan 10 percent owner 3570 LAKEVIEW DRIVE, DELRAY BEACH FL 33445